Sign In
Section Navigation
Common TitleTARHEEL
Official Title Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)
Phase Phase IV
ClinicalTrials.gov NCT00005764
Categories PharmacologyTreatment-ExperiencedAdverse EffectsSwitch/Simplification
Funding
IndustryGlaxo Wellcome
References
  • Lonergan JT, McComsey GA, Fisher RL, et al. Lack of Recurrence of hyperlactatemia in HIV-Infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr. 2004;36:935-42.
    [PubMed Abstract]
  • McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 2004;38:263-70.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.